masupirdine (SUVN-502) / Suven Life Sci  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
masupirdine (SUVN-502) / Suven Life Sci
NCT02580305: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Not Appicable Jul 2019 - Aug 2019 : Top-line efficacy results
Checkmark Data estimate
Oct 2018 - Oct 2018: Data estimate
Checkmark Completion of enrollment in P2a trial for Alzheimer's disease
Oct 2018 - Oct 2018: Completion of enrollment in P2a trial for Alzheimer's disease
More
Completed
2a
564
US
SUVN-502, Masupirdine, Placebo, Donepezil, Namzaric, Memantine, Namenda XR®
Suven Life Sciences Limited
Alzheimer's Disease
11/19
11/19

Download Options